NASDAQ:DXR

Daxor Q2 2025 Earnings Results & Report

Daxor logo
$8.10 -0.25 (-2.99%)
Closing price 03:49 PM Eastern
Extended Trading
$8.07 -0.03 (-0.31%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Daxor reported Q2 2025 earnings on March 2, 2026. The company reported EPS of -$0.1010.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Daxor EPS Results

Actual EPS
-$0.1010
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Daxor Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Daxor Q2 2025 Earnings FAQ

Daxor (NASDAQ:DXR) reported earnings of -$0.1010 per share for Q2 2025. The report was announced on Monday, March 2, 2026.

Daxor Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Daxor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daxor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daxor and other key companies, straight to your email.

About Daxor

Daxor (NASDAQ:DXR) is a medical technology company focused on blood-volume measurement and personalized blood management. Founded in 1970, the company develops diagnostic tools intended to help clinicians assess a patient’s blood volume and support treatment decisions.

Its flagship product, the BVA-100 Blood Volume Analyzer, is an FDA-cleared system that measures total blood volume as well as red blood cell and plasma volumes. The system is designed for use in clinical settings, where these measurements can help inform care for patients with conditions such as heart failure and other fluid-management challenges.

Daxor’s products and related services are directed primarily at healthcare providers and medical institutions. The company’s work centers on making blood-volume analysis available as a clinical tool to support individualized patient care.

View Daxor Profile